Fig. 1From: Emerging therapies for non-small cell lung cancerReported acquired resistance to osimertinib and corresponding potential strategies. Preclinical and clinical data consisted of EGFR-dependent/independent resistant mechanism to osimertinib were included. Additional corresponding TKI with osimertinib may be available in other oncogene-driven resistance, and whether checkpoint inhibitors would be beneficial in pan-negative patients after osimertinib or treatment failure was yet to be answered. TBP, treatment beyond progressionBack to article page